Cargando…

Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder

Background: Urinary incontinence (UI) is a common and refractory complication for patients with neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB). Objectives: To evaluate the effect of Botulinum toxin A (BTX-A) based on different dosages strategy for UI. Method: The MEDL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Qin-Qin, Xu, Yu-Qiong, Xu, Jun, Ding, Xiao-Yan, Guo, Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974921/ https://www.ncbi.nlm.nih.gov/pubmed/32009968 http://dx.doi.org/10.3389/fphar.2019.01618

Ejemplares similares

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
por: Liao, Limin, et al.
Publicado: (2022)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages
por: Gu, Hui-Yun, et al.
Publicado: (2017)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Botulinum toxin-A for the treatment of overactive bladder: UK contributions
por: Seth, JH, et al.
Publicado: (2013)

Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder
por: Barba, Marta, et al.
Publicado: (2022)

Socioeconomic Costs of Overactive Bladder and Stress Urinary Incontinence in Korea
por: Sung, Wooseuk, et al.
Publicado: (2012)

The Association Between Urinary Tract Infection and Overactive Bladder Treatment
por: Liao, Kuang-Ming, et al.
Publicado: (2022)

Toileting behaviors, urinary cues, overactive bladder, and urinary incontinence in older women
por: O’Connell, Kathleen A., et al.
Publicado: (2022)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence
por: Maeda, Takahiro, et al.
Publicado: (2017)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

The effect of vitamin D deficiency in children with overactive bladder related urinary incontinence
por: Özçift, Burak, et al.
Publicado: (2022)

Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
por: Cohen, Brian L., et al.
Publicado: (2009)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population
por: Lai, H. Henry, et al.
Publicado: (2016)

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment
por: Mahajan, Rajiv, et al.
Publicado: (2011)

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A
por: Wang, Chung-Cheng, et al.
Publicado: (2020)

Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children
por: Tan, Denise Jia Yun, et al.
Publicado: (2022)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

The Changes of Voiding Pattern After Midurethral Sling Between Pure Stress Urinary Incontinence and Stress Urinary Incontinence With Overactive Bladder Group
por: Kim, Sun Wook, et al.
Publicado: (2014)

OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)
por: Yokoyama, Osamu, et al.
Publicado: (2020)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
por: Mohanty, N. K., et al.
Publicado: (2008)

Urinary biomarkers of overactive bladder
por: Tian, Xiao-Jun, et al.
Publicado: (2019)

Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo‐controlled, double‐blind trial with an open‐label extension
por: Honda, Masashi, et al.
Publicado: (2021)

Ultrasound-assisted intravesical botulinum toxin A delivery attenuates acetic acid—induced bladder hyperactivity in rats
por: Liu, Qinggang, et al.
Publicado: (2023)

NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice
por: Xie, Xiang, et al.
Publicado: (2021)

Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence
por: Lee, Sang Keun, et al.
Publicado: (2014)

Sexual Disorders in Women with Overactive Bladder and Urinary Stress Incontinence Compared to Controls: A Prospective Study
por: Naumann, Gert, et al.
Publicado: (2021)

Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy
por: Stahlschmidt, Rebeca, et al.
Publicado: (2020)

A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder
por: Al-Azzawi, Issam S., et al.
Publicado: (2020)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

Impact of smoking habit on overactive bladder symptoms and incontinence in women
por: Kawahara, Takashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c8jfqtfv3nto6r8u3tu2mutkkv